Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218048

SCHEMBL23218048

SCHEMBL23218048

CCOC(=O)Cc1ccccc1OCc1coc2c(CN(C)C)cc(Br)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TBXAS1 P24557 1/20 0.39
▸ PKM P14618 1/20 0.36
▸ CFD P00746 2/20 0.36
▸ CCR5 P51681 1/20 0.35
▸ SLC1A5 Q15758 1/20 0.35
▸ MAPT P10636 4/20 0.35
▸ TP53 P04637 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ SLC6A2 P23975 3/20 0.34
▸ SLC6A4 P31645 3/20 0.34
▸ SLC6A3 Q01959 3/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ PTGER1 P34995 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ DUSP3 P51452 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853013 1.00 TBXAS1 (0.39) TBXAS1PKMCFDCCR5SLC1A5
SCHEMBL29592670 1.00 TBXAS1 (0.39) TBXAS1PKMCFDCCR5SLC1A5
SCHEMBL29852719 0.89 TBXAS1 (0.35) TBXAS1PKMCFDCCR5SLC1A5
SCHEMBL23218932 0.89 TBXAS1 (0.35) TBXAS1PKMCFDCCR5SLC1A5
SCHEMBL29853078 0.89 TBXAS1 (0.40) TBXAS1PKMCFDSLC1A5MAPT
SCHEMBL23218822 0.89 TBXAS1 (0.40) TBXAS1PKMCFDSLC1A5MAPT
SCHEMBL23218255 0.88 TBXAS1 (0.41) TBXAS1PKMCFDSLC1A5MAPT
SCHEMBL29592551 0.88 TBXAS1 (0.41) TBXAS1PKMCFDSLC1A5MAPT
SCHEMBL29852978 0.88 TBXAS1 (0.41) TBXAS1PKMCFDSLC1A5MAPT
SCHEMBL23218504 0.88 TBXAS1 (0.35) TBXAS1PKMCFDCCR5SLC1A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TBXAS1 963/4885PKM 4623/4885CFD 1/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TBXAS1 392/4885PKM 4501/4885CFD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.